Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578565 · ClinicalTrials.gov registry record · Phase 3
Rituximab in Rheumatoid Arthritis Lung Disease
A Phase 3 study of Rheumatoid Arthritis and Interstitial Pneumonia, sponsored by Eric Matteson.
- Completed
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT00578565 is a Phase 3 study of Rheumatoid Arthritis and Interstitial Pneumonia that has completed, run by Eric Matteson. The registered enrollment target is 10 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00578565, a Phase 3 study of Rheumatoid Arthritis and Interstitial Pneumonia, has completed, sponsored by Eric Matteson.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks. Safety of rituximab therapy in this disease will be assessed through patient history, physical exams and laboratory parameters. * Twelve male/or female patient with RA-associated lung disease (6 of each nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP) histological subtype) will be enrolled * The study involves 12 visits over 48 weeks * Rituximab will be administered intravenously at Day 1 and Day 15 with repeat dosing at six months.
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578565
The ClinicalTrials.gov registry entry for NCT00578565 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The listed sponsor is Eric Matteson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00578565 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00578565 about?
NCT00578565 is a clinical study titled "Rituximab in Rheumatoid Arthritis Lung Disease". This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks. Safety of rituximab therapy in this disease will be assessed through patient history, physic...
What is the current status of trial NCT00578565?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2007-05. Estimated completion is 2011-06.
What conditions does trial NCT00578565 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Interstitial Pneumonia.
What interventions are being tested in trial NCT00578565?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00578565?
This trial is sponsored by Eric Matteson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00578565 being conducted?
This trial has 2 study locations across Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.